Chapter 7: Achievements and limitations of cervical cytology screening.

PubWeight™: 1.86‹?› | Rank: Top 3%

🔗 View Article (PMID 16950019)

Published in Vaccine on August 31, 2006

Authors

Henry C Kitchener1, Philip E Castle, J Thomas Cox

Author Affiliations

1: Academic Unit of Obstetrics & Gynaecology, University of Manchester, St. Mary's Hospital, Whitworth Park, Manchester, UK. henry.kitchener@cmmc.nhs.uk

Associated clinical trials:

Acceptability of Human Papillomavirus (HPV) Vaccine in Female Sex Workers (Girasol) | NCT00925288

Articles citing this

Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol (2008) 2.91

Using biomarkers as objective standards in the diagnosis of cervical biopsies. Am J Surg Pathol (2010) 1.70

Modeling cervical cancer prevention in developed countries. Vaccine (2008) 1.61

Cervical cancer prevention in low- and middle-income countries: feasible, affordable, essential. Cancer Prev Res (Phila) (2011) 1.50

Looking ahead: a case for human papillomavirus testing of self-sampled vaginal specimens as a cervical cancer screening strategy. Int J Cancer (2011) 1.41

Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting. Obstet Gynecol (2009) 1.41

Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Popul Health Metr (2007) 1.39

Cervical cancer prevention--cervical screening: science in evolution. Obstet Gynecol Clin North Am (2007) 1.07

Lower cost strategies for triage of human papillomavirus DNA-positive women. Int J Cancer (2013) 1.02

Different cervical cancer screening approaches in a Chinese multicentre study. Br J Cancer (2009) 0.98

HPV and cervical cancer: screening or vaccination? Br J Cancer (2008) 0.97

Cervical cancer screening in low-resource settings: A cost-effectiveness framework for valuing tradeoffs between test performance and program coverage. Int J Cancer (2015) 0.95

Risk factors for nonadherence with Pap testing in HIV-infected women. J Womens Health (Larchmt) (2011) 0.92

Neither one-time negative screening tests nor negative colposcopy provides absolute reassurance against cervical cancer. Int J Cancer (2009) 0.90

Development and characterization of the cobas human papillomavirus test. J Clin Microbiol (2013) 0.90

Program spending to increase adherence: South African cervical cancer screening. PLoS One (2009) 0.89

Abnormal anal cytology in HIV-infected women. Am J Obstet Gynecol (2010) 0.88

Characteristics of 44 cervical cancers diagnosed following Pap-negative, high risk HPV-positive screening in routine clinical practice. Gynecol Oncol (2011) 0.86

Factors associated with time to colposcopy after abnormal Pap testing in HIV-infected women. J Womens Health (Larchmt) (2011) 0.84

Cervical and female breast cancers in the Americas: current situation and opportunities for action. Bull World Health Organ (2013) 0.83

How protective is cervical cancer screening against cervical cancer mortality in developing countries? The Colombian case. BMC Health Serv Res (2010) 0.83

Underscreened Women Remain Overrepresented in the Pool of Cervical Cancer Cases in Spain: A Need to Rethink the Screening Interventions. Biomed Res Int (2015) 0.82

Single nucleotide polymorphisms in DNA repair genes and risk of cervical cancer: A case-control study. Oncol Lett (2011) 0.81

Cost-Effectiveness of Different Cervical Screening Strategies in Islamic Republic of Iran: A Middle-Income Country with a Low Incidence Rate of Cervical Cancer. PLoS One (2016) 0.80

Improving cervical cancer screening rates in an urban HIV clinic. AIDS Care (2014) 0.79

Human papillomavirus-related diseases in HIV-infected individuals. Curr Opin Oncol (2008) 0.78

Rationale and design of a multicenter prospective cohort study for the eVALuation and monitoring of HPV infections and relATEd cervical diseases in high-risk women (VALHIDATE study). BMC Cancer (2012) 0.78

The DNA load of six high-risk human papillomavirus types and its association with cervical lesions. BMC Cancer (2015) 0.77

Human papillomavirus and other genital infections in indigenous women from Paraguay: a cross-sectional analytical study. BMC Infect Dis (2013) 0.77

Cervical cancer prevention in reproductive health services: knowledge, attitudes and practices of midwives in Côte d'Ivoire, West Africa. BMC Health Serv Res (2014) 0.77

Good agreements between self and clinician-collected specimens for the detection of human papillomavirus in Brazilian patients. Mem Inst Oswaldo Cruz (2014) 0.77

Cost-effectiveness of HPV-based cervical cancer screening in the public health system in Nicaragua. BMJ Open (2017) 0.77

Screening of cervical cancer in Catalonia 2006-2012. Ecancermedicalscience (2015) 0.76

The Prevalence of Human Papilloma Virus (HPV) in Women using Liquid Base Pap Smear in Rasht, Northern of Iran. J Clin Diagn Res (2015) 0.75

Assessment of the performance of algorithms for cervical cancer screening: evidence from the Ludwig-McGill cohort study. Gynecol Oncol (2012) 0.75

The high prevalence of HPV and HPV16 European variants in cervical and anal samples of HIV-seropositive women with normal Pap test results. PLoS One (2017) 0.75

The performance of tele-cervicography for detection of preinvasive and invasive disease of the uterine cervix as an adjunctive test to Pap smears. Contemp Oncol (Pozn) (2016) 0.75

A Low-Cost HPV Immunochromatographic Assay to Detect High-Grade Cervical Intraepithelial Neoplasia. PLoS One (2016) 0.75

International Image Concordance Study to Compare a Point-of-Care Tampon Colposcope With a Standard-of-Care Colposcope. J Low Genit Tract Dis (2017) 0.75

Evidence-based policy choices for efficient and equitable cervical cancer screening programs in low-resource settings. Cancer Med (2017) 0.75

Self-sampling to improve cervical cancer screening coverage in Switzerland: a randomised controlled trial. Br J Cancer (2017) 0.75

Articles by these authors

Human papillomavirus and cervical cancer. Lancet (2007) 12.47

2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA (2002) 6.55

The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst (2005) 6.03

Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol (2011) 5.59

American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin (2012) 5.58

The carcinogenicity of human papillomavirus types reflects viral evolution. Virology (2005) 4.72

Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst (2011) 4.59

Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology (2004) 3.85

Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis (2005) 3.84

Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst (2009) 3.77

Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol (2004) 3.67

Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer (2009) 3.64

A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis (2007) 3.59

American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol (2012) 3.51

Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst (2008) 3.32

The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J Low Genit Tract Dis (2012) 3.19

American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis (2012) 3.15

Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst (2003) 3.08

The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol (2007) 2.91

American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin (2007) 2.81

Cervical cancer prevention: new tools and old barriers. Cancer (2010) 2.68

Special commentary: patient safety and the next generation of HPV DNA tests. Am J Clin Pathol (2010) 2.65

Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol (2010) 2.61

Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res (2006) 2.33

2001 consensus guidelines for the management of women with cervical intraepithelial neoplasia. Am J Obstet Gynecol (2003) 2.25

Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J Low Genit Tract Dis (2013) 2.18

Practice improvement in cervical screening and management (PICSM): symposium on management of cervical abnormalities in adolescents and young women. J Low Genit Tract Dis (2010) 2.03

Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method. J Natl Cancer Inst (2012) 1.86

A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia. Cancer Res (2010) 1.82

A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study. Cancer Epidemiol Biomarkers Prev (2011) 1.82

Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet (2002) 1.78

Breast and cervical cancer screening utilization among Hispanic women living near the United States-Mexico border. J Womens Health (Larchmt) (2011) 1.74

A comparison of a prototype PCR assay and hybrid capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal papanicolaou smears. Am J Clin Pathol (2005) 1.73

Using biomarkers as objective standards in the diagnosis of cervical biopsies. Am J Surg Pathol (2010) 1.70

Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS). J Natl Cancer Inst (2002) 1.68

The promise of global cervical-cancer prevention. N Engl J Med (2005) 1.67

Detection of precancerous cervical lesions is differential by human papillomavirus type. Cancer Res (2009) 1.67

Human papillomavirus type 18 DNA load and 2-year cumulative diagnoses of cervical intraepithelial neoplasia grades 2-3. J Natl Cancer Inst (2009) 1.65

Comparison of the cobas Human Papillomavirus (HPV) test with the hybrid capture 2 and linear array HPV DNA tests. J Clin Microbiol (2011) 1.65

Human papillomavirus: epidemiology and public health. Arch Pathol Lab Med (2003) 1.61

Risk estimation for the next generation of prevention programmes for cervical cancer. Lancet Oncol (2009) 1.60

Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev (2004) 1.56

Can HPV-16 genotyping provide a benchmark for cervical biopsy specimen interpretation? Am J Clin Pathol (2008) 1.56

Increasing incidence of testicular germ cell tumors among black men in the United States. J Clin Oncol (2005) 1.55

Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa. Int J Cancer (2011) 1.53

A comparison of linear array and hybrid capture 2 for detection of carcinogenic human papillomavirus and cervical precancer in ASCUS-LSIL triage study. Cancer Epidemiol Biomarkers Prev (2008) 1.53

A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination. Int J Cancer (2012) 1.47

Preventing cervical cancer globally by acting locally: if not now, when? J Natl Cancer Inst (2010) 1.46

Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. J Infect Dis (2006) 1.45

Improved sensitivity of vaginal self-collection and high-risk human papillomavirus testing. Int J Cancer (2011) 1.42

Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J Infect Dis (2003) 1.40

The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med (2012) 1.38

Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3. J Natl Cancer Inst (2012) 1.38

How to evaluate emerging technologies in cervical cancer screening? Int J Cancer (2009) 1.37

Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive. J Low Genit Tract Dis (2013) 1.36

Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women. J Infect Dis (2009) 1.35

Detection of genomic amplification of the human telomerase gene (TERC) in cytologic specimens as a genetic test for the diagnosis of cervical dysplasia. Am J Pathol (2003) 1.33

Predictors of human papillomavirus persistence among women with equivocal or mildly abnormal cytology. Int J Cancer (2010) 1.32

Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results. J Low Genit Tract Dis (2013) 1.27

Clinical utility of HPV genotyping. Gynecol Oncol (2006) 1.26

An analysis of high-risk human papillomavirus DNA-negative cervical precancers in the ASCUS-LSIL Triage Study (ALTS). Obstet Gynecol (2008) 1.26

Smoking is a risk factor for cervical intraepithelial neoplasia grade 3 among oncogenic human papillomavirus DNA-positive women with equivocal or mildly abnormal cytology. Cancer Epidemiol Biomarkers Prev (2005) 1.24

Five-year risks of CIN 2+ and CIN 3+ among women with HPV-positive and HPV-negative LSIL Pap results. J Low Genit Tract Dis (2013) 1.20

Etiologic heterogeneity for cervical carcinoma by histopathologic type, using comparative age-period-cohort models. Cancer Epidemiol Biomarkers Prev (2009) 1.18

Relationship between cigarette smoking and human papilloma virus types 16 and 18 DNA load. Cancer Epidemiol Biomarkers Prev (2009) 1.18

Fertility and taxon-specific sperm binding persist after replacement of mouse sperm receptors with human homologs. Dev Cell (2003) 1.17

Simultaneous measurement of several cytokines using small volumes of biospecimens. Cancer Epidemiol Biomarkers Prev (2002) 1.16

Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease. Cancer Epidemiol Biomarkers Prev (2006) 1.14

Benefits and risks of HPV testing in cervical cancer screening. Lancet Oncol (2010) 1.14

HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood. Vaccine (2005) 1.14

Effectiveness of a simple rapid human papillomavirus DNA test in rural Nigeria. Int J Cancer (2012) 1.12

An evaluation of novel, lower-cost molecular screening tests for human papillomavirus in rural China. Cancer Prev Res (Phila) (2013) 1.10

Detection of cervical cancer and its precursors by endocervical curettage in 13,115 colposcopically guided biopsy examinations. Am J Obstet Gynecol (2010) 1.09

Viral load in the natural history of human papillomavirus type 16 infection: a nested case-control study. J Infect Dis (2011) 1.08

A population-based evaluation of cervical screening in the United States: 2008-2011. Cancer Epidemiol Biomarkers Prev (2013) 1.08

Cervical cancer prevention--cervical screening: science in evolution. Obstet Gynecol Clin North Am (2007) 1.07

Letter to the editor regarding "Evaluation of a cervicography-based program to ensure quality of visual inspection of the cervix in HIV-infected women in Johannesburg, South Africa" by Firnhaber et al. J Low Genit Tract Dis (2015) 1.07

Interobserver agreement in the evaluation of digitized cervical images. Obstet Gynecol (2007) 1.06

Risk of cervical precancer and cancer among HIV-infected women with normal cervical cytology and no evidence of oncogenic HPV infection. JAMA (2012) 1.06

Human papillomavirus genotyping after denaturation of specimens for Hybrid Capture 2 testing: feasibility study for the HPV persistence and progression cohort. J Virol Methods (2007) 1.05

Comprehensive control of human papillomavirus infections and related diseases. Vaccine (2013) 1.02

Lower cost strategies for triage of human papillomavirus DNA-positive women. Int J Cancer (2013) 1.02

Acceptability and usability of self-collected sampling for HPV testing among African-American women living in the Mississippi Delta. Womens Health Issues (2013) 1.01

Cervical cytology specimen adequacy: patient management guidelines and optimizing specimen collection. J Low Genit Tract Dis (2008) 1.01

2001 Consensus Guidelines for the Management of Women with Cervical Cytological Abnormalities. J Low Genit Tract Dis (2002) 1.01

Cervical carcinoma rates among young females in the United States. Obstet Gynecol (2012) 1.00

Viral determinants of human papillomavirus persistence following loop electrical excision procedure treatment for cervical intraepithelial neoplasia grade 2 or 3. Cancer Epidemiol Biomarkers Prev (2007) 1.00

Interobserver reproducibility and accuracy of p16/Ki-67 dual-stain cytology in cervical cancer screening. Cancer Cytopathol (2014) 0.99

Human papillomavirus DNA remains detectable longer than related cervical cytologic abnormalities. J Infect Dis (2002) 0.98

A comparison of dacron versus Flocked nylon swabs for anal cytology specimen collection. Acta Cytol (2011) 0.97

Risk factors for anal HPV infection and anal precancer in HIV-infected men who have sex with men. J Infect Dis (2013) 0.97

Cervical cytology of atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion (ASC-H): characteristics and histologic outcomes. Cancer (2006) 0.97

Feasibility study of a human papillomavirus E6 oncoprotein test for diagnosis of cervical precancer and cancer. J Clin Microbiol (2010) 0.96

Further analysis of the ARTISTIC trial. Lancet Oncol (2009) 0.96

Human papillomavirus genotype attribution and estimation of preventable fraction of anal intraepithelial neoplasia cases among HIV-infected men who have sex with men. J Infect Dis (2012) 0.95

Persistence of concurrent infections with multiple human papillomavirus types: a population-based cohort study. J Infect Dis (2011) 0.95

Five-year risks of CIN 3+ and cervical cancer among women with HPV-positive and HPV-negative high-grade Pap results. J Low Genit Tract Dis (2013) 0.94

Lessons from practice: risk of CIN 3 or cancer associated with an LSIL or HPV-positive ASC-US screening result in women aged 21 to 24. J Low Genit Tract Dis (2010) 0.93